Investigational drug · Phase 3
Basimglurant
Also called: NOE-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Trigeminal Neuralgia, Tuberous Sclerosis Complex.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Basimglurant"
First trial start
2022
Jan 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Basimglurant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Trigeminal Neuralgia
- Tuberous Sclerosis Complex
Largest trials
Live from ClinicalTrials.gov: studies naming "Basimglurant" as an intervention, largest first.
- An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.Pivotal-lookingActive, not recruiting
Noema Pharma AGIndustry
NCT05217628 · 166 participants · Start Jan 11, 2022 · Primary completion Feb 2, 2027
Drug: Basimglurant · For: Trigeminal Neuralgia
Sites: La Jolla, California; Miami, Florida; Tampa, Florida · 34 sites in all
Noema Pharma AGIndustry
NCT05059327 · 61 participants · Start Mar 3, 2022 · Primary completion Feb 6, 2025
Drug: Basimglurant with crossover to Placebo; Placebo with crossover to Basimglurant · For: Tuberous Sclerosis Complex
Sites: Los Angeles, California; Baltimore, Maryland; Boston, Massachusetts · 27 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02433093 · 56 participants · Start Apr 2015 · Primary completion Sep 2015
Drug: Basimglurant; Placebo · For: Major Depressive Disorder, Healthy Volunteer
Sites: Garden Grove, California
Newest research
PubMed records naming it or its code names, newest first.
- Medical management of refractory trigeminal neuralgia.
Stern JI, Chiang CC, Robertson CE · Curr Opin Neurol 2026
- Clinical investigations of compounds targeting metabotropic glutamate receptors.
Witkin JM, Pandey KP, Smith JL · Pharmacol Biochem Behav 2022
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL, Hurducas C, Hawton K, et al. · Cochrane Database Syst Rev 2021
- Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID, Park LT, Zarate CA · CNS Drugs 2021
- Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies.
Bennett KA, Sergeev E, MacSweeney CP, et al. · J Pharmacol Exp Ther 2021
- Combining In Vivo and Organotypic In Vitro Approaches to Assess the Human Relevance of Basimglurant (RG7090), a Potential CAR Activator.
Nudischer R, Renggli K, Bertinetti-Lapatki C, et al. · Toxicol Sci 2020
Also in development for Trigeminal Neuralgia
- SR750Phase 21 trial
Shanghai SIMR Biotechnology Co., Ltd. · Trigeminal Neuralgia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.